CI – The Cigna Group

Cigna Group (CI) Monthly Stock Report – November 27, 2025

Company Overview

The Cigna Group, based in Bloomfield, Connecticut, stands as a prominent player in the Healthcare Plans industry within the broader Healthcare sector in the U.S. With a rich history dating back to 1792, Cigna has evolved into a leading provider of various insurance and related services. These include medical, pharmacy, dental, and behavioral health coverage tailored for both insured and self-insured customers.

Cigna operates through its diverse subsidiaries and offers services domestically and internationally. Its Evernorth Health Services segment enhances its portfolio by providing coordinated health services like pharmacy benefits and innovative care delivery solutions catering to health plans, employers, and government entities. With an impressive total revenue of approximately $268.08 billion, Cigna’s robust business model positions it favorably within an increasingly competitive healthcare landscape.

52-Week Price Performance Analysis

The stock price performance of Cigna (CI) over the past year reflects considerable volatility and bearish momentum. Currently trading at $278.35, the stock is situated notably below its 52-week high of $350.00 and rather close to its 52-week low of $239.51, illustrating the challenges faced in recent trading sessions.

Technical Insights:

• The stock has recorded a 16.02% decline from its peak, illustrating the bearish trend that has prevailed throughout the year.
• Analysts have identified key support near the $278.35 mark, which has already been tested recently, suggesting it could become a critical buying opportunity if held. Should this level fail, we anticipate further downward movement.
• Resistance has been strongly established around the $340 level, having faced multiple tests without a successful breakout, indicating persistent selling pressure at this zone.
• The 50-day moving average stands at $285.51, further emphasizing the downward trend, as CI consistently fails to remain above this key trend line.

The recent price action shows a slight rebound from the support level, but confidence remains subdued due to sustained bearish momentum. Investors are advised to monitor for potential breaks either above the moving average or below the support to gauge upcoming price movements.

Financial Performance and Metrics

Cigna demonstrated solid financial health, characterized by impressive revenues and profits. As of the latest reporting, the company’s total revenue stood at approximately $268.08 billion, reflecting robust demand for its healthcare services. Here are some critical metrics:

• EBITDA: Approximately $11.65 billion, which positions the company with favorable operational profitability.
• Current Stock Price: $278.35, indicating a position below the 50-day moving average and the recent highs.
• Shares Outstanding: A total of 267,125,816 shares are outstanding.
• Short Interest: With 3,934,852 shares short (approximately 1.95% of the float), this relatively low short interest implies a cautiously optimistic investor sentiment.

Despite these solid figures, recent projections indicate potential challenges ahead, particularly in the pharmacy benefits segment, which could impact future profitability.

Recent News and Developments

Recent activities surrounding Cigna reflect a mix of stability and concern:

1. Dividend Declaration: Cigna announced a quarterly cash dividend of $1.51 per share, maintaining a commendable 44-year streak of dividend payouts. This dividend is payable on December 18, 2025, to shareholders on record as of December 4, 2025.

2. Strong Q2 Results: In its recent second-quarter report, Cigna recorded total revenues of $67.2 billion, up 11% year-over-year, predominantly driven by its Evernorth Health Services and specialty pharmacy divisions. Adjusted income from operations reached $1.9 billion ($7.20 per share), with the company reaffirming its outlook for adjusted income from operations of at least $29.60 per share for 2025.

3. Third-Quarter Performance: Despite surpassing analyst revenue estimates with $69.74 billion, Cigna’s adjusted income from operations decreased by 1% to $2.09 billion. Margin pressures in its pharmacy benefit services segment were anticipated, contributing to a decline in stock value.

Analysts have responded to these latest financial highlights with mixed ratings and lowered price targets, indicative of a cautious sentiment surrounding Cigna’s future performance.

Market Sentiment and Analyst Recommendations

As of November 27, 2025, analyst sentiment towards Cigna is presented through varying recommendations:

• Bernstein: Maintained a “Market Perform” rating, adjusting the price target from $346 to $294.
• JP Morgan: Retained an “Overweight” rating but reduced its price target from $428 to $375.
• Wells Fargo: Held an “Equal-Weight” recommendation, with a price target cut from $354 to $300.

Market sentiment remains tempered, reflecting caution among analysts amid anticipated challenges that may put pressure on Cigna’s margins, particularly in the pharmacy space.

Conclusion and Investment Consideration

Cigna’s strategic position and strong historical performance make it a worthy consideration for investors. Nonetheless, potential investors should weigh the advantages of the upcoming dividend, robust revenue growth, and long-term outlook against the backdrop of current price trends, operational pressures, and mixed analyst sentiments.

With the current trading price sitting at $278.35 and analysts projecting a high target of $378.00, investors may find attractive upside potential if they navigate the prevailing risks carefully. Conversely, close monitoring of the $278.35 support level will be crucial for determining whether a bullish reversal could materialize or if further declines are imminent.

Buyers should stay alert to market developments and analyst updates to make informed investment decisions within this dynamic healthcare industry.

Metric	Value
Market Cap	$74.4b
Total Debt	$34.0b
Total Cash	$6.9b
Shares Outstanding	267.1m
Float Shares	265.9m